Karolinska Mammography Project
for Risk Prediction of Breast Cancer

The KARMA study is supported by the Märit and Hans Rausing Initiative Against Breast Cancer, the Swedish Research Council, the Swedish Cancer Society, the Kamprad Foundation, and Stockholm County Council.

Karolinska Mammography Project
for Risk Prediction of Breast Cancer

The KARMA study is supported by the Märit and Hans Rausing Initiative Against Breast Cancer, the Swedish Research Council, the Swedish Cancer Society, the Kamprad Foundation, and Stockholm County Council.

2017-12-23

Karisma 2 clinical trial on tamoxifen for preventive use is halfway through

The Karisma 2 trial on dose optimisation of tamoxifen for preventive use has now reached 800 participants in Lund and in Stockholm and has thereby reached the halfway through milestone. Karisma 2 in expected to close the inclusion by December 2018.

Karolinska Mammography Project for Risk Prediction of Breast Cancer

The KARMA study is supported by the Märit and Hans Rausing Initiative Against Breast Cancer, the Swedish Research Council, the Swedish Cancer Society, the Kamprad Foundation, and Stockholm County Council.

Karolinska Mammography Projectfor Risk Prediction of Breast Cancer

The KARMA study is supported by the Märit and Hans Rausing Initiative Against Breast Cancer, the Swedish Research Council, the Swedish Cancer Society, the Kamprad Foundation, and Stockholm County Council.

2017-12-23

Karisma 2 clinical trial on tamoxifen for preventive use is halfway through

Karolinska Mammography Project
for Risk Prediction of Breast Cancer

Karolinska Mammography Project
for Risk Prediction of Breast Cancer